The 2026 National Medical Insurance Catalog has added the world's first-in-class EGFR×HER3 bispecific antibody ADC drug, Rongkangyilongtudan Monoclonal Antibody for Injection, for the later-line treatment of recurrent or metastatic nasopharyngeal carcinoma, effective January 1, 2027. The drug was approved for marketing in June 2026 and secured medical insurance coverage less than half a year after launch. Four government departments jointly issued a document to remove obstacles hindering innovative drugs from entering hospitals, exempting Class 1 new drugs from relevant performance indicators and clearing bottlenecks to implementation. The drug has demonstrated significant efficacy in the later-line treatment of nasopharyngeal carcinoma and has received first-choice recommendations backed by Class 1A evidence from three clinical guidelines. Clinical studies are currently underway across more than ten types of solid tumors, with multiple tumor types already showing impressive data. The relevant policies signal to the industry a clear direction of supporting original innovation with high clinical value, driving China's innovative drugs from quantitative growth toward a qualitative leap.
